BRITISH AMERICAN TOBACCO (BATS.L) analysis, July 17, 2026

Key Updates

British American Tobacco (BATS.L) has rebounded sharply by +4.35% to £4,673 since the July 9 report (£4,478), fully recovering the two-leg pullback that followed the June 29 restructuring announcement and returning to the precise level at which that initial restructuring-driven rally peaked. This move confirms the £4,478 area as a near-term support level and restores the stock to its YTD high zone. The sole new catalyst is a criminal investigation by federal and local authorities into former New York City Sheriff Anthony M. Miranda and his alleged ties to BAT subsidiaries Reynolds American and R.J. Reynolds Tobacco, introducing a fresh, albeit preliminary, legal risk to the investment thesis.

Current Trend

BATS.L is in a confirmed uptrend across all measured timeframes, with momentum accelerating materially in the near term:

• YTD: +10.89% — the primary trend remains constructively bullish, consistent with the recovery narrative established since the June 29 restructuring catalyst.
• 6-month: +8.02% — sustained medium-term appreciation supports the view that the structural re-rating is ongoing.
• 1-month: +4.52% and 5-day: +4.73% — near-term momentum has re-accelerated following the consolidation trough at £4,478.
• The stock has now traced a clear pattern: spike to £4,674 (June 29) → pullback to £4,478 (July 9) → recovery to £4,673 (July 17), forming a constructive higher-low structure relative to pre-restructuring levels.

Investment Thesis

The core thesis rests on BAT's strategic pivot from structurally declining combustible cigarettes toward high-growth smoke-free alternatives (Vuse vapes, Velo nicotine pouches), supported by an aggressive cost transformation programme designed to protect margins and fund reinvestment. The £600 million annualised cost savings target by 2028, achieved through a ~19% workforce reduction and AI-enabled operations, provides a credible earnings floor even as combustible volumes deteriorate. Simultaneously, regulatory tailwinds — exemplified by the FDA's approval of Philip Morris's Zyn pouches as a reduced-risk product — signal a favourable framework for oral nicotine products across the sector, including BAT's Velo brand. The dividend yield, underpinned by over $34 billion in 2025 worldwide revenue, remains a key total-return anchor.

Thesis Status

The thesis is broadly intact but incrementally challenged by the newly disclosed criminal investigation. The price recovery to £4,673 — effectively re-testing the June 29 post-announcement high — confirms that the market continues to price the restructuring as a net positive. However, the federal inquiry into BAT subsidiaries Reynolds American and R.J. Reynolds Tobacco introduces a non-trivial tail risk: potential findings of federal program fraud, bribery, wire fraud, or money laundering could expose BAT to reputational damage, regulatory scrutiny, or financial liability in its most important market. The investigation is at an early stage (subpoenas issued), and the market's +4.35% move suggests this risk has not been materially discounted yet — warranting close monitoring. The FDA's positive stance on nicotine pouches (Zyn approval) remains a sector-wide positive for BAT's Velo portfolio.

Key Drivers

The following factors are currently driving BATS.L price action and fundamental outlook:

• Criminal investigation into BAT subsidiaries (NEW): Federal and local authorities have issued subpoenas seeking records from Reynolds American and R.J. Reynolds Tobacco in connection with an investigation into former NYC Sheriff Anthony Miranda. Alleged crimes include federal program fraud, bribery, wire fraud, and money laundering. BAT was actively lobbying against menthol bans and unauthorised e-cigarette sales — areas central to the investigation's context. This is the primary new risk introduced since the last report. New York Times, 17 Jul 2026
• Workforce restructuring programme: The elimination of ~9,000 roles (19% of global headcount) via 5,500 direct cuts and 3,500 outsourced positions, targeting £600 million in annual savings by 2028, remains the dominant fundamental driver. US operations are unaffected. BBC, 29 Jun 2026 | Financial Times, 29 Jun 2026
• FDA approval of Zyn as reduced-risk product: The FDA's authorisation for Philip Morris to market Zyn nicotine pouches with explicit risk-reduction claims is a sector-wide regulatory precedent. Jefferies analysts noted the ruling benefits BAT and Altria alongside PMI, supporting the regulatory pathway for BAT's Velo brand. Financial Times, 30 Jun 2026
• Smoke-free alternatives growth: BAT's Vuse vapes and Velo nicotine pouches are reported to be growing at mid-teen percentage rates, partially offsetting steeper-than-expected declines in traditional cigarette volumes. The Guardian, 29 Jun 2026
• AI and technology transformation: The Accenture outsourcing partnership and broader AI integration strategy underpin the operational efficiency narrative, positioning BAT as a leaner, technology-enabled business by 2028. The Guardian, 29 Jun 2026

Technical Analysis

BATS.L at £4,673 is testing the key resistance zone established at the June 29 post-restructuring spike high of approximately £4,674. A decisive close above this level would represent a technical breakout and open the path toward new YTD highs. Key levels to monitor:

• Resistance: £4,673–£4,674 — the June 29 spike high, now being re-tested. A sustained break above confirms bullish continuation.
• Support: £4,478 — the July 9 trough, now confirmed as near-term support following the current recovery leg.
• Secondary support: ~£4,361 — the pre-restructuring base from June 19, representing the broader technical floor.
• The price structure — spike, pullback to higher low, recovery — is consistent with a healthy consolidation and continuation pattern within the prevailing uptrend.
• The +4.35% single-period move, combined with a +4.73% 5-day gain, indicates above-average momentum; however, the coincidence with the criminal investigation news introduces event-driven volatility risk at this resistance level.

Bull Case

• 1. £600 million cost savings programme provides durable earnings uplift: The restructuring of ~19% of the global workforce, targeting £600 million in annualised savings by 2028 via direct cuts and Accenture outsourcing, represents a material, quantified improvement to the cost base — directly supporting earnings per share and dividend sustainability even against a backdrop of combustible volume decline. Financial Times, 29 Jun 2026 | Bloomberg, 29 Jun 2026
• 2. FDA regulatory framework increasingly supportive of oral nicotine alternatives: The FDA's approval of Zyn pouches as a reduced-risk product — with explicit claims covering lung cancer, mouth cancer, emphysema, and stroke risk reduction — establishes a meaningful regulatory precedent that analysts at Jefferies explicitly identify as beneficial to BAT and its Velo brand, expanding the addressable market for smoke-free products. Financial Times, 30 Jun 2026
• 3. Smoke-free alternatives delivering mid-teen growth, offsetting combustible decline: Vuse vapes and Velo nicotine pouches are growing at mid-teen percentage rates, demonstrating that BAT's portfolio transition is generating real revenue momentum in growth categories, with guidance for smoke-free revenue raised despite overall volume pressures. The Guardian, 29 Jun 2026
• 4. Revenue scale and cash generation underpin dividend resilience: BAT reported over $34 billion in worldwide revenue in 2025, providing a substantial cash generation base to fund the dividend, absorb restructuring costs, and invest in smoke-free alternatives simultaneously — a key differentiator versus smaller peers. New York Times, 17 Jul 2026
• 5. AI and technology integration positions BAT for structural margin expansion: The partnership with Accenture and broader shift to AI-enabled operations, including supply-network consolidation in the UK and Singapore, positions BAT to structurally reduce its operating cost ratio beyond the immediate headcount savings, supporting long-term margin expansion. The Guardian, 29 Jun 2026 | Morningstar, 29 Jun 2026

Bear Case

• 1. Federal criminal investigation into Reynolds American and R.J. Reynolds Tobacco (NEW): Federal and local prosecutors have issued subpoenas to BAT's US subsidiaries in connection with an investigation into alleged federal program fraud, bribery, wire fraud, and money laundering linked to former NYC Sheriff Miranda. As the US is BAT's most significant market and Reynolds American is excluded from the restructuring (implying strategic importance), any adverse findings could result in material financial liability, regulatory penalties, or reputational damage at a critical juncture in the company's turnaround. New York Times, 17 Jul 2026
• 2. Steeper-than-expected combustible volume declines accelerating structural revenue erosion: BAT's own disclosures confirm that traditional cigarette volumes are declining faster than anticipated in 2026, the primary driver behind the restructuring. This pace of volume deterioration risks outrunning the growth trajectory of smoke-free alternatives, creating a revenue gap that cost savings alone may not fully bridge. Morningstar, 29 Jun 2026 | BBC, 29 Jun 2026
• 3. Workforce reduction of ~19% introduces execution and operational risk: Eliminating approximately 9,000 roles — including supply-network and global service hub functions transferred to Accenture — while simultaneously transforming to AI-enabled operations carries significant execution risk. Disruption to operations, loss of institutional knowledge, or outsourcing integration failures could delay or reduce the projected £600 million savings. Financial Times, 29 Jun 2026 | Wall Street Journal, 29 Jun 2026
• 4. Competitive pressure from PMI's Zyn approval intensifies smoke-free market rivalry: The FDA's authorisation of Zyn as a formally reduced-risk product gives Philip Morris a significant first-mover regulatory advantage in the nicotine pouch segment, potentially enabling superior marketing claims over BAT's Velo brand and accelerating market share concentration in PMI's favour within the fastest-growing nicotine category. Financial Times, 30 Jun 2026
• 5. Regulatory and lobbying exposure amplified by investigation context: BAT's active lobbying against menthol cigarette bans and unauthorised e-cigarette sales — activities cited in the context of the criminal investigation — could attract heightened regulatory scrutiny of its US advocacy activities, potentially constraining its ability to influence policy outcomes that are material to its combustible and smoke-free product strategies. New York Times, 17 Jul 2026